{"id":44901,"date":"2021-07-08T12:50:00","date_gmt":"2021-07-08T10:50:00","guid":{"rendered":"https:\/\/www.stille.se\/us\/mfn_news\/stille-acquires-swiss-st-ag\/"},"modified":"2024-02-23T11:53:50","modified_gmt":"2024-02-23T10:53:50","slug":"stille-acquires-swiss-st-ag","status":"publish","type":"mfn_news","link":"https:\/\/www.stille.se\/us\/news\/stille-acquires-swiss-st-ag\/","title":{"rendered":"Stille Acquires Swiss S&T\u00a0AG"},"content":{"rendered":"
Stille AB (publ) today signed a contract to acquire 100 percent of the shares in the Swiss company S&T AG with development, manufacturing and sales of microsurgical instruments in the absolute premium segment.<\/strong><\/div>\n

S&T AG was founded in 1966 and has its headquarters and manufacturing in Neuhausen, Switzerland. S&T is globally recognized as one of the world\u2019s leading manufacturers of high-quality microsurgical instruments. The company\u2019s products are marketed through around 50 distributors throughout the world, with the US, the UK and Germany as the most important markets.<\/p>\n

\u201dThe acquisition of S&T means unifying the industry\u2019s two most high-quality manufacturers of surgical instruments in the premium segment. This brings significant value for Stille's business. Stille\u2019s product offering within microsurgery is now strongly complemented and the two companies\u2019 respective distribution channels offer great opportunities for increased sales\u201d<\/em>, comments Stille\u2019s CEO Hanna Ernestam Wilkman.\u00a0<\/p>\n

S&T has 20 employees and for the split business year that ended on June 30th, 2021, the preliminary turnover amounts to MCHF 6.1 with an adjusted EBITDA around MCHF 1.6. The acquisition will also include the German sister company S&T GmbH, whose primary function has been to facilitate the export of products from the Swiss company to the European Union.<\/p>\n

MCHF 6.0 is paid cash upon the transaction and financed through Stille\u2019s existing cash liquidity and bank loans. Additionally, MCHF 2.5 is being paid in compensation shares which, with the support of the mandate provided by the annual meeting on May 4th, 2021, new shares are being issued without shareholders\u2019 preferential rights. In addition, a further contingent consideration of maximum MCHF 3.0 may be paid earliest 18 months after the acquisition based on the achievement of certain company goals. The purchase price for the German subsidiary S&T GmbH amounts to \u20ac25,000, which is equivalent to the share capital in the company.\u00a0<\/p>\n

The transaction was signed and will also be closed today, July 8th, 2021. S&T AG will become a part of Stille\u2019s business area Surgical Instruments. Markus Spingler, CEO at S&T AG, will become the new business unit manager at Stille, with global responsibility for the business area. Markus will also be part of Stille\u2019s management team.\u00a0<\/p>\n

\u201dStille and S&T have followed each other at a distance for many years, and it feels great to now have the opportunity to develop and grow together. I look forward to being a part of Stille\u2019s organization and integrating our two businesses\u201d<\/em>, says S&T\u2019s CEO Markus Spingler.<\/p>\n

\u201dWe have a clear strategy and growth agenda at Stille. It is satisfying to now have succeeded in acquiring a company that meets our high expectations regarding focus, profitability and growth potential. The acquisition marks an important step in Stille\u2019s continued journey in becoming a leading actor within the premium segment for surgical instruments\u201d<\/em>, says Stille\u2019s Chairman of the Board Lars Kvarnhem.<\/p>\n

Torsh\u00e4lla, July 8th, 2021.<\/p>\n

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA SOUTH AFRICA, HONGKONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES.<\/span><\/p>\n

\n

For more information, please contact:<\/span><\/span><\/p>\n

Hanna Ernestam Wilkman<\/span><\/span><\/strong>
\nCEO
\n+46 (0)72 402 10 88 | hanna.e.wilkman@stille.se<\/span><\/span><\/p>\n<\/div>\n

\n

STILLE AB (publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world\u2019s oldest medical device companies. Stille\u2019s main business areas are surgical instruments and c-arm tables. Stille\u2019s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures, the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality.<\/span><\/span><\/p>\n

The share is listed on First North Growth Market under the acronym \u201cSTIL\u201d with Eminova AB as Certified Adviser. Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. This information is such information that Stille AB is obliged to disclose according to the EU\u2019s market abuse regulation. The information was, through the agency of the contact person above, rendered for publication on July 8th,\u00a02021, at\u00a012.50\u00a0(CET).<\/span><\/span><\/p>\n

For more information about Stille visit www.stille.se<\/span><\/span><\/p>\n<\/div>\n